5LU Stock Chart & Stats
€0.01
<€0.01(90.00%)
At close: 4:00 PM EST
€0.01
<€0.01(90.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.02
Previous CloseN/A
Volume5.00K
Average Volume (3M)15.00K
Market Cap
€15.10M
Enterprise Value€205.61M
Total Cash (Recent Filing)€7.99M
Total Debt (Recent Filing)€89.69M
Price to Earnings (P/E)―
Beta-9.70
Next Earnings
Nov 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding1,349,793,200
10 Day Avg. Volume15,000
30 Day Avg. Volume15,000
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-76.69
Price to Sales (P/S)22.32
P/FCF Ratio-2.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Microalgae Product PlatformThe company operates across biotechnology and nutrition, giving it a defined platform for developing algae-derived ingredients and products. A focused microalgae capability can support repeated product development and participation in nutritional applications over the medium term.
Dual Commercialization ModelSelling both finished products and ingredients provides two commercialization routes for the same underlying algae technology. If execution improves, this model could support broader market access through consumer channels while also enabling business-to-business adoption.
Improved Net Result Versus 2025A modest year-over-year improvement in the net result indicates some movement in the right direction despite continued losses. If this improvement is sustained and accompanied by better gross economics, it could form an early step toward stabilizing financial performance.
Bears Say
Revenue Contraction And Negative Gross ProfitShrinking revenue combined with negative gross profit shows that the current business is not generating enough sales to cover direct costs. This weak operating foundation limits internal funding capacity and makes a durable path to profitability uncertain over the next several quarters.
Extreme Leverage And Minimal EquityNear-zero equity relative to substantial debt leaves very little balance-sheet protection and severely restricts financial flexibility. The resulting leverage increases refinancing and dilution risk, while limiting the company’s ability to absorb further operating losses or fund development internally.
Persistent Cash BurnContinued negative operating and free cash flow means the business consumes cash rather than financing operations from internally generated funds. Dependence on external funding can constrain investment, increase financing pressure, and weaken resilience if losses persist.
5LU FAQ
What was Simris Alg AB Class B’s price range in the past 12 months?
Simris Alg AB Class B lowest stock price was <€0.01 and its highest was €0.02 in the past 12 months.
What is Simris Alg AB Class B’s market cap?
Simris Alg AB Class B’s market cap is €15.10M.
When is Simris Alg AB Class B’s upcoming earnings report date?
Simris Alg AB Class B’s upcoming earnings report date is Nov 11, 2026 which is in 17 days.
How were Simris Alg AB Class B’s earnings last quarter?
Simris Alg AB Class B released its earnings results on Aug 12, 2026. The company reported >-€0.001 earnings per share for the quarter.
Is Simris Alg AB Class B overvalued?
According to Wall Street analysts Simris Alg AB Class B’s price is currently Overvalued.
Does Simris Alg AB Class B pay dividends?
Simris Alg AB Class B does not currently pay dividends.
What is Simris Alg AB Class B’s EPS estimate?
Simris Alg AB Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Simris Alg AB Class B have?
Simris Alg AB Class B has 1,349,793,200 shares outstanding.
What happened to Simris Alg AB Class B’s price movement after its last earnings report?
Simris Alg AB Class B reported an EPS of >-€0.001 in its last earnings report. Following the earnings report the stock price went up 100%.
Which hedge fund is a major shareholder of Simris Alg AB Class B?
Currently, no hedge funds are holding shares in DE:5LU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Simris Alg AB Class B
Operating both within Sweden and across global markets, Simris Alg AB (publ) specializes in the production and sale of nutritional supplements and food products derived from algae. Its product portfolio includes Simris Algae Omega-3, a unique plant-derived marine omega-3 supplement providing both EPA and DHA. Additionally, under its 'Simris Select' brand, the company provides a range of other algae-based items like premium chlorella, spirulina sprinkles, invigorating astaxanthin, and various algae teas such as 'flower power' and 'sun candy'. Established in 2010, the firm maintains its main office in Hammenhög, Sweden.
Technical Analysis
Infant Bacterial Therapeutics AB
―
Magle Chemoswed Holding AB
―
Biosergen AB
―
Bioextrax AB
―
Bio-Works Technologies AB
―